23andMe_Logo_grey.png
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024 16:05 ET | 23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
Harish Consul
Biongevity Enhances Longevity Strategy with Harish Consul as Chief Venture Capital Advisor
September 04, 2024 09:49 ET | BioAro
Biongevity appoints Harish Consul as Chief Venture Capital Advisor, accelerating global growth with innovative precision health and longevity strategies.
23andMe_Logo_grey.png
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024 07:30 ET | 23andMe, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy...
baylor-logo-wire-500x500.jpg
Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024
March 04, 2024 10:00 ET | Baylor Genetics
Researchers present abstracts and poster sessions showcasing research and clinical solutions. Joint session planned with Illumina.
website-logo (2).png
Epigenetics Market Predicted to Garner USD 12.7 Billion By 2033, At CAGR 19.2% | Exclusive Report by Marketresearch.biz
January 16, 2024 03:58 ET | MarketResearch.biz
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The epigenetics market was valued at USD 2.3 billion in 2023 with a significant growth and is projected to reach at USD 12.7 billion by 2033 with a CAGR...
baylor-logo-wire-500x500.jpg
Baylor Genetics Accelerates Growth, Combines Clinical and Scientific Expertise with Commercial Capabilities to Meet Increased Needs of Patients, Providers and Partners
January 03, 2024 10:00 ET | Baylor Genetics
Company Expands Test Offerings, Lab Technology, and Customer-Centric Tools Rapid Comprehensive Whole Genome and Exome Sequencing, Disease-Specific Panels and Customizable Solutions Advance Diagnoses...
Photo Collage (Optimi)
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
November 28, 2023 07:42 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
NeuroQure Logo.png
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
November 06, 2023 12:00 ET | NeuroQure
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...
SHMNLogo.jpg
SOHM Collaborates with University of Arizona Center for Innovation to Advance ABBIE, a Groundbreaking Non-Viral Gene-Editing Technology
October 10, 2023 09:30 ET | SOHM, Inc.
CHINO HILLS, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs...
Synlogic_Logo_Blue.png
Synlogic to Participate in Chardan’s Genetic Medicines Conference
September 21, 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...